Vital Therapies, Inc. (NASDAQ:VTL) Director Muneer A. Satter purchased 100,000 shares of the stock in a transaction that occurred on Wednesday, December 13th. The stock was acquired at an average cost of $5.48 per share, with a total value of $548,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Vital Therapies, Inc. (VTL) traded down $0.10 during mid-day trading on Thursday, hitting $5.50. The stock had a trading volume of 224,015 shares, compared to its average volume of 153,132. Vital Therapies, Inc. has a 1-year low of $2.25 and a 1-year high of $6.50.

Vital Therapies (NASDAQ:VTL) last posted its quarterly earnings data on Wednesday, October 25th. The company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.02. During the same period last year, the company earned ($0.32) earnings per share. sell-side analysts predict that Vital Therapies, Inc. will post -1.26 EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP acquired a new stake in shares of Vital Therapies in the third quarter valued at approximately $116,000. JPMorgan Chase & Co. raised its stake in shares of Vital Therapies by 1,985.3% during the third quarter. JPMorgan Chase & Co. now owns 25,462 shares of the company’s stock worth $123,000 after purchasing an additional 24,241 shares during the last quarter. New York State Common Retirement Fund purchased a new stake in shares of Vital Therapies during the third quarter worth approximately $213,000. Dowling & Yahnke LLC purchased a new stake in shares of Vital Therapies during the third quarter worth approximately $252,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of Vital Therapies by 1.8% during the first quarter. Goldman Sachs Group Inc. now owns 64,545 shares of the company’s stock worth $258,000 after purchasing an additional 1,157 shares during the last quarter. 24.35% of the stock is owned by institutional investors and hedge funds.

VTL has been the subject of a number of research analyst reports. ValuEngine raised Vital Therapies from a “strong sell” rating to a “sell” rating in a report on Saturday, October 21st. BidaskClub raised Vital Therapies from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 5th. Zacks Investment Research downgraded Vital Therapies from a “hold” rating to a “sell” rating in a report on Tuesday, October 31st. Finally, Raymond James Financial reissued a “buy” rating on shares of Vital Therapies in a report on Tuesday, December 5th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $8.00.

TRADEMARK VIOLATION NOTICE: This article was originally published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/14/insider-buying-vital-therapies-inc-vtl-director-buys-100000-shares-of-stock.html.

Vital Therapies Company Profile

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Insider Buying and Selling by Quarter for Vital Therapies (NASDAQ:VTL)

Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.